Technical Analysis for GLUE - Monte Rosa Therapeutics, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| 200 DMA Resistance | Bearish | 0.00% | |
| Non-ADX 1,2,3,4 Bearish | Bearish Swing Setup | 0.00% | |
| Bollinger Band Squeeze | Range Contraction | 0.00% | |
| Gapped Up | Strength | 0.00% | |
| Up 3 Days in a Row | Strength | 0.00% | |
| Stochastic Buy Signal | Bullish | 4.60% | |
| Bollinger Band Squeeze | Range Contraction | 4.60% | |
| Gapped Up | Strength | 4.60% | |
| Oversold Stochastic | Weakness | 4.60% | |
| Pocket Pivot | Bullish Swing Setup | 5.66% |
| Alert | Time |
|---|---|
| 10 DMA Resistance | about 22 hours ago |
| Rose Above 200 DMA | about 22 hours ago |
| Gap Up Partially Closed | about 23 hours ago |
| Rose Above Previous Day's High | about 23 hours ago |
| 200 DMA Resistance | about 23 hours ago |
Get this analysis on your stocks daily!
- Earnings date: 05/09/2024
Monte Rosa Therapeutics, Inc. Description
Monte Rosa Therapeutics is a biotechnology company developing a portfolio of novel small molecule precision medicines that employ the body’s natural mechanisms to selectively degrade therapeutically relevant proteins. The company has developed a proprietary protein degradation platform, called QuEEN™, that enables it to rapidly identify protein targets and molecular glue degrader, or MGD, product candidates that are designed to eliminate therapeutically relevant proteins in a highly selective manner. The company’s drug discovery platform combines diverse and proprietary chemical libraries of small molecule protein degraders with in-house proteomics, structural biology, machine learning-based target selection and computational chemistry capabilities to predict and obtain protein degradation profiles. Monte Rosa was launched from founding investor Versant Ventures’ Ridgeline Discovery Engine and is headquartered in Boston, Mass., with research operations in both Boston and Basel, Switzerland.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Drug Discovery Machine Learning Proteomics
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 8.84 |
| 52 Week Low | 2.44 |
| Average Volume | 142,792 |
| 200-Day Moving Average | 5.38 |
| 50-Day Moving Average | 6.29 |
| 20-Day Moving Average | 5.45 |
| 10-Day Moving Average | 5.32 |
| Average True Range | 0.47 |
| RSI (14) | 42.20 |
| ADX | 16.58 |
| +DI | 17.54 |
| -DI | 23.69 |
| Chandelier Exit (Long, 3 ATRs) | 5.05 |
| Chandelier Exit (Short, 3 ATRs) | 6.03 |
| Upper Bollinger Bands | 6.07 |
| Lower Bollinger Band | 4.84 |
| Percent B (%b) | 0.32 |
| BandWidth | 22.42 |
| MACD Line | -0.34 |
| MACD Signal Line | -0.32 |
| MACD Histogram | -0.0211 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 5.78 | ||||
| Resistance 3 (R3) | 5.79 | 5.62 | 5.69 | ||
| Resistance 2 (R2) | 5.62 | 5.48 | 5.61 | 5.66 | |
| Resistance 1 (R1) | 5.42 | 5.39 | 5.52 | 5.41 | 5.63 |
| Pivot Point | 5.26 | 5.26 | 5.30 | 5.25 | 5.26 |
| Support 1 (S1) | 5.06 | 5.12 | 5.16 | 5.05 | 4.83 |
| Support 2 (S2) | 4.89 | 5.03 | 4.88 | 4.80 | |
| Support 3 (S3) | 4.70 | 4.89 | 4.77 | ||
| Support 4 (S4) | 4.68 |
